Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05844488 · ClinicalTrials.gov registry record
DIGITAL Biomarker: Blood Based Biomarkers in the Primary Care Setting for Alzheimer's Disease
A clinical trial, sponsored by Indiana University.
- Completed
- Registry status
- 26
- Enrollment target
NCT05844488 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 26 participants.
The verdict
NCT05844488 has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the feasibility of implementing blood-based biomarker testing for amyloid positivity designed to aid the early detection of Alzheimer's Disease and Related Dementia (ADRD) in patients 65+ including the rate that patients and providers follow up abnormal blood-based biomarker testing.
Interventions
- DEVICE PrecivityAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2023-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05844488
The ClinicalTrials.gov registry entry for NCT05844488 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PrecivityAD is the first listed.
NCT05844488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05844488 about?
NCT05844488 is a clinical study titled "DIGITAL Biomarker: Blood Based Biomarkers in the Primary Care Setting for Alzheimer's Disease". The primary objective of this study is to evaluate the feasibility of implementing blood-based biomarker testing for amyloid positivity designed to aid the early detection of Alzheimer's Disease and Related Dementia (ADRD) in patients 65+ including the rate that patients and providers follow up abno...
What is the current status of trial NCT05844488?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2023-03-31. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05844488?
The interventions under investigation include: PrecivityAD (DEVICE).
Who is sponsoring clinical trial NCT05844488?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.